
CLOV Stock Forecast & Price Target
CLOV Analyst Ratings
Bulls say
Clover Health Investments is poised for long-term success with the recent announcement of favorable 2026 CMS rates, strong member retention rates of over 95%, and a proven track record of strong membership growth and SG&A leverage. With their innovative Clover Assistant platform driving improved medical cost ratios, their focus on high growth markets and attractive pricing strategies will continue to drive market share and membership growth, making them a valuable player in the healthcare technology industry.
Bears say
Clover Health Investments is facing potential headwinds in 2027 due to its transition back to 3.5-star payment and a potential flat rate year-on-year, which may impact profitability if not managed effectively. Additionally, there is uncertainty surrounding the outcome of a lawsuit appealing the star rating change and the final CMA MA advance notice. The company has a track record of profitability, but its ability to sustain this in light of these potential challenges and a competitive market is a concern. These factors contribute to a negative outlook on the stock.
This aggregate rating is based on analysts' research of Clover Health Investments and is not a guaranteed prediction by Public.com or investment advice.
CLOV Analyst Forecast & Price Prediction
Start investing in CLOV
Order type
Buy in
Order amount
Est. shares
0 shares